Arcutis Biotherapeutics, Inc. (ARQT) vs Parabilis Medicines, Inc. (PBLS)

A side-by-side comparison of Arcutis Biotherapeutics, Inc. and Parabilis Medicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arcutis Biotherapeutics, Inc. logo
ARQT
Arcutis Biotherapeutics, Inc.
$3.03B
$24.21HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Parabilis Medicines, Inc. logo
PBLS
Parabilis Medicines, Inc.
$3.33B
$28.57HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT

Total return — ARQT vs PBLS

growth of $100 · dividends reinvested · last 1y
ARQT +18.5% (+18.5%/yr)PBLS +47.7% (+47.7%/yr)PBLS compounded faster over this window
100150200Start $100$118$148
ARQT PBLS

ARQT vs PBLS: by the numbers

  • •PBLS is the larger company ($3.33B vs $3.03B market cap).
  • •ARQT is profitable (6.15% net margin) while PBLS runs a net loss (0.00%).

Metrics side by side

Valuation

MetricARQTPBLS
P/E ratio116.10N/A
Forward P/E48.69N/A
P/S ratio6.53N/A
P/B ratio13.733.18
EV / EBITDA83.54N/A
FCF yield1.29%N/A

Profitability

MetricARQTPBLS
Gross margin91.14%0.00%
Operating margin-3.25%0.00%
Net margin6.15%0.00%
ROE12.93%N/A
ROIC9.95%-409.85%

Growth (annualized)

MetricARQTPBLS
Total return CAGR (5Y)-0.28%N/A

Frequently asked

Is ARQT or PBLS more profitable?
ARQT runs the higher net margin — ARQT at 6.15% versus PBLS at 0.00%.

Go deeper

Full ARQT analysisFull PBLS analysisInteractive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratioArcutis Biotherapeutics ROEParabilis Medicines ROEArcutis Biotherapeutics operating marginParabilis Medicines operating marginArcutis Biotherapeutics revenue growthParabilis Medicines revenue growthArcutis Biotherapeutics free cash flowParabilis Medicines free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.